<DOC>
	<DOCNO>NCT00718081</DOCNO>
	<brief_summary>The purpose study evaluate dosage ARX-F01 ( opioid pain medication ) versus placebo ( sugar pill ) treatment post-operative pain subject follow abdominal surgery . We hypothesize subject receive placebo poor pain relief drop study sooner often ARX-F01 treated subject .</brief_summary>
	<brief_title>A Multicenter , Randomized , Placebo-Controlled Phase 2 Study Evaluate Clinical Efficacy , Safety , Tolerability ARX-F01 Sublingual Sufentanil Patients Undergoing Major Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Sufentanil</mesh_term>
	<criteria>Inclusion Criteria Screening : 1 . Male female patient 18 80 year age . 2 . Patient schedule undergo upper low abdominal surgery general anesthesia . 3 . Patient must classify American Society Anesthesiologists ( ASA ) class I III . 4 . Patient must Body Mass Index [ BMI = weight ( kg ) /height ( m2 ) ] 18 39 , inclusively . 5 . Female patient childbearing potential must use effective method birth control screen visit end study . Acceptable method birth control include oral transdermal contraceptive , condom , spermicidal foam , intrauterine device ( IUD ) , progestin implant injection , abstinence , vaginal ring , sterilization partner . The reason nonchildbearing potential , bilateral tubal ligation , bilateral oophorectomy , hysterectomy , postmenopausal ≥1 year , must specify patient 's case report form ( CRF ) . 6 . The patient must willing able understand study procedure use pain scale , communicate meaningfully study personnel . 7 . The patient must provide write informed consent sign Informed Consent Exclusion Criteria Screening : 1 . Patient schedule undergo laparoscopicallyassisted abdominal surgery . 2 . Patient previously respond opioid analgesic treatment pain . 3 . Patient currently take take opioid 30 consecutive day daily use daily dose equivalent great 15 mg morphine within past 3 month prior surgery ( e.g . 3 dos per day Vicodin® , Norco® , Lortab® 5 mg hydrocodone per tablet ) . 4 . Patient allergy hypersensitivity opioids . 5 . Patient currently sleep apnea document sleep laboratory study . 6 . Patient screen laboratory test value outside laboratory normal range consider clinically significant Investigator . 7 . Patient woman pregnant lactating . 8 . Patient psychiatric disease encephalopathy severe enough prevent patient provide reliable study documentation . 9 . Patient , Investigator 's judgment , adequate ability read understand English . 10 . Patient medical condition , Investigator 's opinion , could adversely impact patient 's participation safety , conduct study , interfere pain assessment , include chronic abdominal pain active infection . 11 . Patient clinically significant renal liver impairment could affect metabolism clearance sufentanil . 12 . Patient painful physical condition acute abdominal pain , opinion Investigator , may confound postoperative pain assessment . 13 . Patient history drug , prescription medicine , alcohol abuse within past 2 year positive drug screen test cocaine , amphetamine , barbiturate , phencyclidine , methadone screening . 14 . Patient receive oxygen therapy time screen . 15 . Patient participate clinical trial investigational drug device within 30 day screen visit schedule receive investigational product ARXF01 participate study . Exclusion Criteria Randomization ( early PACU time period ) : 1 . Patient respiratory rate le 8 breath per minute great 24 breath per minute . 2 . Patient arterial oxygen saturation pulse oximetry ( SpO2 ) less 90 % supplemental oxygen . 3 . Patient able answer question follow command . 4 . Patient vomit responsive standard treatment . 5 . The surgical procedure incision closure longer 4 hour . 6 . There deviation surgical anesthetic protocol specify Section 6.1.2.1. approve Institutional Review Board ( IRB ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>